Rapport Therapeutics Inc Trading Halted, Volatility Trading Pause

TipRanksMar 4 10:25 ET

Express News | Rapport Therapeutics : Intends to Initiate Additional Phase 2a Trial of Rap-219 in Bipolar Mania in Q3 2025 With Topline Data Expected in H1 of 2027

ReutersMar 3 07:17 ET

Express News | Rapport Therapeutics Announces Appointment of DR. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

ReutersMar 3 07:00 ET

Press Release: Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Dow JonesMar 3 07:00 ET

Rapport Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswireFeb 24 07:00 ET

Stifel Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $35

Moomoo NewsFeb 10 23:31 ET · Ratings